@article {Ouldali2022.01.17.22269263, author = {Na{\"\i}m Ouldali and Haleh Bagheri and Francesco Salvo and Denise Antona and Antoine Pariente and Claire Leblanc and Martine Tebacher and Jo{\"e}lle Micallef and Corinne Levy and Robert Cohen and Etienne Javouhey and Brigitte Bader-Meunier and Caroline Ovaert and Sylvain Renolleau and Veronique Hentgen and Isabelle Kone-Paut and Nina Deschamps and Lo{\"\i}c De Pontual and Xavier Iriart and Christelle Gras-Le Guen and Fran{\c c}ois Angoulvant and Alexandre Belot and the {\textquotedblleft}French Covid-19 Paediatric Inflammation Consortium{\textquotedblright} and the {\textquotedblleft}French Pharmacovigilance network{\textquotedblright}}, title = {Multisystemic inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study}, elocation-id = {2022.01.17.22269263}, year = {2022}, doi = {10.1101/2022.01.17.22269263}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Importance Multisystem inflammatory syndrome in children (MIS-C) is the most severe life-threatening clinical entity associated with pediatric SARS-CoV-2 infection. Whether COVID-19 mRNA vaccine can induce this complication in children is unknown.Objective To assess the risk of hyper-inflammatory syndrome following COVID-19 mRNA vaccine in children.Design, Setting, and Participants Post-authorization national population-based surveillance using the French enhanced pharmacovigilance surveillance system for COVID-19 vaccines. All cases of suspected hyper-inflammatory syndrome following COVID-19 mRNA vaccine in 12{\textendash} 17-year-old children between June 15th, 2021 and January 1st, 2022, were reported. Each case was assessed for WHO MIS-C criteria. Causality assessment followed 2019 WHO recommendations.Exposure COVID-19 mRNA vaccine.Main Outcome and Measures The main outcome was the reporting rate of post-vaccine hyper-inflammatory syndrome per 1,000,000 COVID-19 mRNA vaccine doses in 12{\textendash}17-year-old children. This reporting rate was compared to the MIS-C rate per 1,000,000 12{\textendash}17-year-old children infected by SARS-CoV-2. Secondary outcomes included the comparison of clinical features between post-vaccine hyper-inflammatory syndrome and post SARS-CoV-2 MIS-C.Results From June 2021 to January 2022, 8,113,058 COVID-19 mRNA vaccine doses were administered to 4,079,234 12{\textendash}17-year-old children. Among them, 9 presented a multisystemic hyper-inflammatory syndrome. All cases fulfilled MIS-C WHO criteria. Main clinical features included male predominance (8/9, 89\%), cardiac involvement (8/9, 89\%), digestive symptoms (7/9, 78\%), coagulopathy (5/9, 54\%), cytolytic hepatitis (4/9, 46\%), and shock (3/9, 33\%). 3/9 (33\%) required intensive care unit transfer, and 2/9 (22\%) hemodynamic support. All cases recovered. Only three cases had evidence of previous SARS-CoV-2 infection. The reporting rate was 1.1 (95\%CI [0.5; 2.1]) per 1,000,000 doses injected. As a comparison, 113 MIS-C (95\%CI [95; 135]) occurred per 1,000,000 12{\textendash}17-year-old children infected by SARS-CoV-2. Clinical features (inflammatory parameters, cytopenia) slightly differed from post-SARS-CoV-2 MIS-C, along with short-term outcomes (less PICU transfer than MIS-C).Conclusion and Relevance Very few cases of hyper-inflammatory syndromes with multi-organ involvement occurred following COVID-19 mRNA vaccine in 12{\textendash}17-year-old children. The low reporting rate of this syndrome, compared to the rate of MIS-C among same age children infected by SARS-CoV-2, supports the benefit of SARS-CoV-2 vaccination in children. Further studies are required to explore specific pathways of this entity compared to post-SARS-CoV-2 MIS-C.Question Is COVID-19 mRNA vaccine in 12-17-year-old children associated with subsequent multisystemic hyper-inflammatory syndrome?Findings The French national pharmacovigilance system identified 9 children with a hyper-inflammatory syndrome with multi-organ involvement following COVID-19 mRNA vaccination (reporting rate 1.1 [0.5; 2.1] per 1,000,000 doses), of which only three had evidence of previous SARS-CoV-2 infection. All cases fulfilled WHO definition for MIS-C, but clinical and immunological features, along with short-term outcomes, slightly differed from classical post SARS-CoV-2 MIS-C.Meaning Very rare cases of hyper-inflammatory syndrome can occur following COVID-19 mRNA vaccine in 12-17-year-old children. The very low rate of this entity, compared to classical post-SARS-CoV-2 MIS-C, supports the benefit of SARS-CoV-2 vaccination in children.Competing Interest StatementNO reports travel grants from GSK, Pfizer, and Sanofi. Dr Javouhey reported receiving grants from CSL Behring. Dr C. Levy reported receiving grants from GlaxoSmithKline, Merck Sharp \& Dohme, and Sanofi and personal fees from Pfizer and Merck. Dr Cohen reported receiving personal fees from GlaxoSmithKline, Pfizer, Sanofi, and Merck Sharp \& Dohme. All other authors have no potential conflicts of interest to disclose.Funding StatementNO was supported by the 2021 ESPID (European Society for Pediatric Infectious Diseases) Fellowship Award. the French Covid-19 Paediatric Inflammation Consortium received an unrestricted grant from the Square Foundation (Grandir Fonds de Solidarity Pour L enfance).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the French INSERM ethics committee for evaluation (IRB00003888). A written information form validated by the ethics committee was given to all participants. Oral consent was obtained from study participants; no family members or participants refused to participate.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors}, URL = {https://www.medrxiv.org/content/early/2022/01/18/2022.01.17.22269263}, eprint = {https://www.medrxiv.org/content/early/2022/01/18/2022.01.17.22269263.full.pdf}, journal = {medRxiv} }